Separately, HC Wainwright reaffirmed a buy rating and issued a $11.00 price objective on shares of Soligenix in a research report on Thursday, September 21st.
Soligenix (NASDAQ SNGX) opened at $2.27 on Wednesday. Soligenix has a 12-month low of $1.74 and a 12-month high of $5.08.
In other Soligenix news, insider Spa Essetifin acquired 293,510 shares of the stock in a transaction that occurred on Wednesday, November 29th. The shares were acquired at an average cost of $2.12 per share, with a total value of $622,241.20. The transaction was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 5.03% of the company’s stock.
Soligenix, Inc is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, and its innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer.
Receive News & Ratings for Soligenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix and related companies with MarketBeat.com's FREE daily email newsletter.